Medpace (MEDP) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Medpace · Health Care · ref. ETF XLV · 54 calls · price $611.57
What the company does: Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
📈 Medpace (MEDP) stock price
$611.57+29.3% over range
Aug 28, 25low $393.42 · high $620.75Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
25% recommend buying · 8 analysts
📊 JPI status : Medpace has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 MEDP price target & analyst consensus — price $612
The price target · all analysts combined (8 targets)
Highest target · 1 firm of 8$692+13.2%
Median target · of 8 targets$604.5-1.2%
Lowest target · 1 firm of 8$450-26.4%
Current price$611.57
Where these 8 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
338%
$624 ↔ $692
Below
563%
$450 ↔ $609
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Jefferies — 64% of its targets hit on this sector (112 calls tested). It aims for $515 (-16 %), call made on July 8, 2026, maturing on July 8, 2027 (51 d ago).
The 6 reliable analysts
$617+0.8 %
The 2 other firms
$525-14 %
How to read it: the 6 reliable firms are not filtered by optimism — 3 aim above the price, 3 below, hence their $617 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 8 ratings (last 6 months)
Strong Buy00%
Buy225%
Hold675%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 MEDP price target all
All 54 calls, one by one, with our verdict on each firm.
→ See all 54 targets, analyst by analyst💡 The best analysts on MEDP most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in MEDP? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Medpace? The JPI assistant answers using our backtest data.
📈 Medpace fundamentals: valuation, margins & growth › open the full page
P/E 35.9Net margin 17.7 %Revenue growth +17.2 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 17 %
2023
Rev +29%Profit +15%
2024
Rev +12%Profit +43%
2025
Rev +20%Profit +12%
🔎 Detailed analyses
🏛️ Which US Congress members hold Medpace (MEDP)?
1 Congress member has disclosed MEDP buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Michael Guest 1× · 42%
✅ Historical analyst reliability on MEDP
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| William Blair ↗ | 100% | +35.2% | 5 |
| Guggenheim ↗ | 75% | +33.5% | 4 |
| Credit Suisse | 70% | +31.3% | 10 |
| Mizuho ↗ | 67% | +23.7% | 3 |
| Truist Securities ↗ | 50% | +27.1% | 2 |
| TD Cowen ↗ | 50% | +10.0% | 4 |
| Baird ↗ | 50% | -10.5% | 8 |
| SunTrust Robinson Humphrey | 33% | -77.5% | 3 |
| UBS ↗ | 20% | -26.5% | 5 |
📊 What $1,000 invested in Medpace would be worth › open the full page
In short — $1,000 invested in Medpace 10 years ago would be worth $17,736 today, i.e. +33%/yr on average. Best year: 2025 (+69%), worst: 2022 (-2%). Price performance, excluding dividends.
If I'd invested $1,000 in Medpace
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,594 | +59% |
| 3 years ago | $2,493 | +149% |
| 5 years ago | $3,805 | +280% |
Return by year (Medpace)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -6% | $943 (-6%) |
| 2025 | +69% | $1,594 (+59%) |
| 2024 | +8% | $1,728 (+73%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Medpace
Loading news…
📋 All analyst calls on MEDP
Filtered on — · ✕ show all
▲ Outperform · 🎯$665
Price at call : $589.37 — upside +13%
Today : $611.57 — upside +9%
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
BMO Capital ↗
Jul 24, 26
■ Market Perform neutral · not a buy · 🎯$600
Price at call : $589.37 — gap to target +2%
Today : $611.57 — gap to target -2%
🎯 on MEDP : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
Truist Securities ↗
Jul 24, 26
■ Hold neutral · not a buy · 🎯$609
Price at call : $589.37 — gap to target +3%
Today : $611.57 — gap to target -0%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
■ Hold neutral · not a buy · 🎯$492
Price at call : $589.37 — gap to target -17%
Today : $611.57 — gap to target -20%
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
RBC Capital ↗
Jul 24, 26
▲ Outperform · 🎯$692
Price at call : $589.37 — upside +17%
Today : $611.57 — upside +13%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
■ Neutral neutral · not a buy · 🎯$624
Price at call : $601.38 — gap to target +4%
Today : $611.57 — gap to target +2%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
▲ Outperform · 🎯$586
Price at call : $530.19 — upside +11%
Today : $611.57 — upside -4%
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
■ Neutral neutral · not a buy · 🎯$547
Price at call : $531.99 — gap to target +3%
Today : $611.57 — gap to target -11%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
See the other 46 calls, newest to oldest
■ Hold neutral · not a buy · 🎯$515
Price at call : $546.29 — gap to target -6%
Today : $611.57 — gap to target -16%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
■ Equal-Weight neutral · not a buy · 🎯$450
Price at call : $421.37 — gap to target +7%
Today : $611.57 — gap to target -26%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Apr 24, 27
matures : Apr 24, 27
BMO Capital ↗
Apr 24, 26
■ Market Perform neutral · not a buy · 🎯$400
Price at call : $421.37 — gap to target -5%
Today : $611.57 — gap to target -35%
🎯 on MEDP : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Apr 24, 27
matures : Apr 24, 27
RBC Capital ↗
Apr 24, 26
▲ Outperform · 🎯$484
Price at call : $421.37 — upside +15%
Today : $611.57 — upside -21%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Apr 24, 27
matures : Apr 24, 27
▲ Outperform · 🎯$477
Price at call : $410.54 — upside +16%
Today : $611.57 — upside -22%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Apr 24, 27
matures : Apr 24, 27
■ Equal-Weight neutral · not a buy · 🎯$500
Price at call : $470.59 — gap to target +6%
Today : $611.57 — gap to target -18%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Mar 6, 27
matures : Mar 6, 27
RBC Capital ↗
Mar 3, 26
▲ Outperform · 🎯$522
Price at call : $465.86 — upside +12%
Today : $611.57 — upside -15%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Mar 3, 27
matures : Mar 3, 27
■ Hold neutral · not a buy · 🎯$419
Price at call : $446.44 — gap to target -6%
Today : $611.57 — gap to target -31%
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : Feb 18, 27
matures : Feb 18, 27
▲ Buy · 🎯$560
Price at call : $428.18 — upside +31%
Today : $611.57 — upside -8%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
▼ Underweight · 🎯$500
Price at call : $423.93 — upside +18%
Today : $611.57 — upside -18%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Truist Securities ↗
Feb 11, 26
■ Hold neutral · not a buy · 🎯$539
Price at call : $423.93 — gap to target +27%
Today : $611.57 — gap to target -12%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Leerink Partners ↗
Feb 11, 26
■ Market Perform neutral · not a buy · 🎯$485
Price at call : $423.93 — gap to target +14%
Today : $611.57 — gap to target -21%
🎯 on MEDP : no call matured yet · 📊 on Health : 54.5% · +10.0% (11 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
▼ Underweight · 🎯$525
Price at call : $558.74 — upside -6%
Today : $611.57 — upside -14%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
BMO Capital ↗
Nov 13, 25
■ Market Perform neutral · not a buy · 🎯$600
Price at call : $591.32 — gap to target +1%
Today : $611.57 — gap to target -2%
🎯 on MEDP : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Nov 13, 26
matures : Nov 13, 26
Truist Securities ↗
Oct 27, 25
■ Hold neutral · not a buy · 🎯$555
Price at call : $580.53 — gap to target -4%
Today : $611.57 — gap to target -9%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Oct 27, 26
matures : Oct 27, 26
▼ Sell · 🎯$462
Price at call : $596.48 — upside -23%
Today : $611.57 — upside -24%
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : Oct 24, 26
matures : Oct 24, 26
▼ Underweight · 🎯$485
Price at call : $596.48 — upside -19%
Today : $611.57 — upside -21%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Oct 24, 26
matures : Oct 24, 26
▲ Outperform · 🎯$655
Price at call : $605.2 — upside +8%
Today : $611.57 — upside +7%
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Oct 24, 26
matures : Oct 24, 26
▲ Outperform · 🎯$575
Price at call : $528.07 — upside +9%
Today : $611.57 — upside -6%
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
in progress (365j)
matures : Oct 17, 26
matures : Oct 17, 26
▼ Underweight · 🎯$425
Price at call : $536.17 — upside -21%
Today : $611.57 — upside -31%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Oct 2, 26
matures : Oct 2, 26
■ Hold neutral · not a buy · 🎯$450
Price at call : $485.59 — gap to target -7%
Today : $611.57 — gap to target -26%
🎯 on MEDP : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Sep 9, 26
matures : Sep 9, 26
Rothschild & Co
Sep 3, 25
■ Neutral neutral · not a buy · 🎯$474
Price at call : $482.34 — gap to target -2%
Today : $611.57 — gap to target -22%
🎯 on MEDP : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Sep 3, 26
matures : Sep 3, 26
▼ Sell · 🎯$305
Price at call : $447.92 — upside -32%
Today : $611.57 — upside -50%
Expected -32% · Actual +31% · Reason (≤ −15%) : ✗ No
🎯 on MEDP : 0% (1 call matured) · 📊 on Health : 49.6% · +18.1% (119 calls)
-30.6%
stock +31% · XLV +24%
matured Jul 29, 26
▲ Outperform · 🎯$510
Price at call : $453.05 — upside +13%
Today : $611.57 — upside -17%
Expected +13% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
+30.1%
stock +30% · XLV +21%
matured Jul 25, 26
Truist Securities ↗
Jul 23, 25
■ Hold neutral · not a buy · 🎯$436
Price at call : $455.68 — gap to target -4%
Today : $611.57 — gap to target -29%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
Deutsche Bank ↗
Jul 23, 25
■ Hold neutral · not a buy · 🎯$430
Price at call : $455.68 — gap to target -6%
Today : $611.57 — gap to target -30%
🎯 on MEDP : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
■ Equal-Weight neutral · not a buy · 🎯$450
Price at call : $437.41 — gap to target +3%
Today : $611.57 — gap to target -26%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
■ Neutral neutral · not a buy · 🎯$490
Price at call : $437.41 — gap to target +12%
Today : $611.57 — gap to target -20%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
▼ Sell · 🎯$366
Price at call : $437.41 — upside -16%
Today : $611.57 — upside -40%
Expected -16% · Actual +39% · Reason (≤ −15%) : ✗ No
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
-38.5%
stock +39% · XLV +18%
matured Jul 23, 26
■ Equal-Weight neutral · not a buy · 🎯$300
Price at call : $315.28 — gap to target -5%
Today : $611.57 — gap to target -51%
🎯 on MEDP : no call matured yet · 📊 on Health : 47.9% · +1.6% (194 calls)
in progress (365j)
matures : Jun 24, 26
matures : Jun 24, 26
Truist Securities ↗
Apr 23, 25
■ Hold neutral · not a buy · 🎯$300
Price at call : $302.88 — gap to target -1%
Today : $611.57 — gap to target -51%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
■ Neutral neutral · not a buy · 🎯$313
Price at call : $290.54 — gap to target +8%
Today : $611.57 — gap to target -49%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
William Blair ↗
Apr 22, 25
■ Market Perform neutral · not a buy
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
in progress (365j)
matures : Apr 22, 26
matures : Apr 22, 26
■ Hold neutral · not a buy · 🎯$328
Price at call : $305 — gap to target +8%
Today : $611.57 — gap to target -46%
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
in progress (365j)
matures : Apr 14, 26
matures : Apr 14, 26
Truist Securities ↗
Apr 10, 25
■ Hold neutral · not a buy · 🎯$333
Price at call : $282.33 — gap to target +18%
Today : $611.57 — gap to target -46%
🎯 on MEDP : no call matured yet · 📊 on Health : 58.7% · +5.8% (109 calls)
in progress (365j)
matures : Apr 10, 26
matures : Apr 10, 26
▲ Outperform · 🎯$355
Price at call : $302.56 — upside +17%
Today : $611.57 — upside -42%
Expected +17% · Actual +66% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (2 calls matureds) · 📊 on Health : 57.1% · +12.3% (70 calls)
+65.8%
stock +66% · XLV +8%
matured Apr 9, 26
Leerink Partners ↗
Mar 24, 25
■ Market Perform neutral · not a buy · 🎯$330
Price at call : $330.59 — gap to target -0%
Today : $611.57 — gap to target -46%
🎯 on MEDP : no call matured yet · 📊 on Health : 54.5% · +10.0% (11 calls)
in progress (365j)
matures : Mar 24, 26
matures : Mar 24, 26
■ Neutral neutral · not a buy · 🎯$362
Price at call : $345.81 — gap to target +5%
Today : $611.57 — gap to target -41%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Jan 27, 26
matures : Jan 27, 26
■ Neutral neutral · not a buy · 🎯$354
Price at call : $337.82 — gap to target +5%
Today : $611.57 — gap to target -42%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Nov 25, 25
matures : Nov 25, 25
▲ Buy · 🎯$372
Price at call : $328.08 — upside +13%
Today : $611.57 — upside -39%
Expected +13% · Actual +84% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 50% (2 calls matureds) · 📊 on Health : 53.8% · +17.8% (26 calls)
+84.5%
stock +84% · XLV -2%
matured Oct 23, 25
■ Neutral neutral · not a buy · 🎯$349
Price at call : $330.07 — gap to target +6%
Today : $611.57 — gap to target -43%
🎯 on MEDP : no call matured yet · 📊 on Health : 48.7% · +1.8% (76 calls)
in progress (365j)
matures : Oct 23, 25
matures : Oct 23, 25
William Blair ↗
Oct 22, 24
▲ Outperform
Actual +81% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
+80.8%
stock +81% · XLV -3%
matured Oct 22, 25
William Blair ↗
Sep 11, 24
▲ Outperform
Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
+42.2%
stock +42% · XLV -11%
matured Sep 11, 25
William Blair ↗
Jul 23, 24
▲ Outperform
Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
+19.3%
stock +19% · XLV -9%
matured Jul 23, 25
William Blair ↗
Jul 31, 18
▲ Outperform
Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
+28.3%
stock +28% · XLV +2%
matured Jul 31, 19
William Blair ↗
Sep 6, 16
▲ Outperform
Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on MEDP : 100% (5 calls matureds) · 📊 on Health : 50% · +37.8% (20 calls)
+5.2%
stock +5% · XLV +11%
matured Sep 6, 17
Frequently asked questions
Should I buy Medpace stock?
This isn't buy advice. For Medpace, the analyst consensus is "Hold", with an average price target of $605 (-1% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (5 calls tracked on Medpace). We show the numbers — you decide.
Is it too late to buy Medpace? How high can it go?
The most bullish analyst target on Medpace is $692 (+13% above today's price); the average is $605. That's the upside they see. Check how reliable those analysts have actually been on Medpace on our site before trusting it.
Is Medpace still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 9 analysts have a real record on Medpace, the best hitting 100% over 5 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Medpace? The case for and against
The arguments for and against, one by one, from the numbers: why invest in MEDP (and why hesitate).
What has Medpace's past performance been?
Historical returns and a "how much if I had invested" calculator: MEDP performance & returns.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX